SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with ...

SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today ...

(RTTNews) - Evoke Pharma Inc. (EVOK), a pharmaceutical company focused on treatments for gastrointestinal diseases, announced on Tuesday that it has received notices of allowance for two additional ...

SOLANA BEACH, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an ...

Evoke Pharma, Inc. announced that it has received a Notice of Allowance from the USPTO for a patent application covering the use of its GIMOTI® (metoclopramide) nasal spray in patients with moderate ...

Shares of Evoke Pharma Inc (NASDAQ:EVOK) are trading sharply higher Wednesday morning after the specialty pharmaceutical company announced it has received a Notice of Allowance from the U.S. Patent ...

(RTTNews) - Shares of Evoke Pharma Inc. (EVOK) are up more than 60% in pre-market trade Monday, following FDA approval of the company's nasal spray, Gimoti, for the relief of symptoms with acute and ...

* Evoke Pharma - based on recent fda discussions, these data are anticipated to be submitted as part of a new drug application for Gimoti * Says trial data was not statistically significant in itt ...

SOLANA BEACH, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced ...

Shares of Evoke Pharma Inc. soared 38% in premarket trade, after the Food and Drug Administration's positive assessment of the company's gastrointestinal disease treatment, Gimoti. The company said ...